551 related articles for article (PubMed ID: 17102939)
1. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
Rakotoniaina Z; Guerard P; Lirussi F; Goirand F; Rochette L; Dumas M; Bardou M
Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):195-206. PubMed ID: 17102939
[TBL] [Abstract][Full Text] [Related]
2. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
Guerard P; Rakotoniaina Z; Goirand F; Rochette L; Dumas M; Lirussi F; Bardou M
Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):401-14. PubMed ID: 16896805
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.
Rakotoniaina Z; Guerard P; Lirussi F; Rochette L; Dumas M; Goirand F; Bardou M
Naunyn Schmiedebergs Arch Pharmacol; 2008 Sep; 378(3):241-51. PubMed ID: 18542928
[TBL] [Abstract][Full Text] [Related]
4. 3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
Satoh M; Satoh A
J Pharm Pharm Sci; 2009 Feb; 11(2):118s-130s. PubMed ID: 19203474
[TBL] [Abstract][Full Text] [Related]
5. Effects of atorvastatin and L-arginine treatments on electrical field stimulation-mediated relaxations in pulmonary arterial rings of monocrotaline-induced pulmonary hypertensive rats.
Ozturk EI; Uma S
J Cardiovasc Pharmacol; 2010 Nov; 56(5):498-505. PubMed ID: 20729759
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin restores the impaired vascular endothelium-dependent relaxations mediated by nitric oxide and endothelium-derived hyperpolarizing factors but not hypotension in sepsis.
Subramani J; Kathirvel K; Leo MD; Kuntamallappanavar G; Uttam Singh T; Mishra SK
J Cardiovasc Pharmacol; 2009 Dec; 54(6):526-34. PubMed ID: 19755915
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin prevents dehydromonocrotaline-induced pulmonary hypertension in beagles.
Chen D; Zhou D; Qian J; Chen F; Guan L; Dong L; Ge J
Exp Lung Res; 2012 Sep; 38(7):333-43. PubMed ID: 22888849
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
9. Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats.
Xie L; Lin P; Xie H; Xu C
Clin Exp Hypertens; 2010; 32(8):547-54. PubMed ID: 21091363
[TBL] [Abstract][Full Text] [Related]
10. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study.
McMurtry MS; Bonnet S; Michelakis ED; Bonnet S; Haromy A; Archer SL
Am J Physiol Lung Cell Mol Physiol; 2007 Oct; 293(4):L933-40. PubMed ID: 17675370
[TBL] [Abstract][Full Text] [Related]
11. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.
Nishimura T; Faul JL; Berry GJ; Vaszar LT; Qiu D; Pearl RG; Kao PN
Am J Respir Crit Care Med; 2002 Nov; 166(10):1403-8. PubMed ID: 12406854
[TBL] [Abstract][Full Text] [Related]
13. The effects of atorvastatin on pulmonary arterial hypertension and expression of p38, p27, and Jab1 in rats.
Gao YF; Zhu XD; Shi DM; Jing ZC; Li L; Ma D; Fan ZX; Li J; Wang YW; Wu BX
Int J Mol Med; 2010 Oct; 26(4):541-7. PubMed ID: 20818494
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress.
Zhou MS; Jaimes EA; Raij L
Hypertension; 2004 Aug; 44(2):186-90. PubMed ID: 15238570
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein.
Beckman JA; Liao JK; Hurley S; Garrett LA; Chui D; Mitra D; Creager MA
Circ Res; 2004 Jul; 95(2):217-23. PubMed ID: 15178637
[TBL] [Abstract][Full Text] [Related]
16. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation.
Wagner AH; Köhler T; Rückschloss U; Just I; Hecker M
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):61-9. PubMed ID: 10634801
[TBL] [Abstract][Full Text] [Related]
17. Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension.
Matsuo S; Saiki Y; Adachi O; Kawamoto S; Fukushige S; Horii A; Saiki Y
J Thorac Cardiovasc Surg; 2015 Mar; 149(3):902-9. PubMed ID: 25454916
[TBL] [Abstract][Full Text] [Related]
18. [Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats].
Li XL; Guan RJ; Xu QH; Wu ZY
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Mar; 39(3):247-53. PubMed ID: 21609531
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ.
Wagner AH; Schwabe O; Hecker M
Br J Pharmacol; 2002 May; 136(1):143-9. PubMed ID: 11976279
[TBL] [Abstract][Full Text] [Related]
20. Prevention of nitrate tolerance by long-term treatment with statins.
Fontaine D; Otto A; Fontaine J; Berkenboom G
Cardiovasc Drugs Ther; 2003 Mar; 17(2):123-8. PubMed ID: 12975593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
